PDF) P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience
European Crohn´s and Colitis Organisation - ECCO - The 13th Congress of ECCO in numbers
Mathematics (Combinatorics) the Colombian Way: ECCO 2018
European Crohn´s and Colitis Organisation - ECCO - P292 Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysis
Julia Ulmschneider
/wall-murals-abstract-polygon-background-brazil-flag-colors-vector.jpg.jpg "Wall Mural Abstract polygon background. Brazil flag colors. Vector. - PIXERS.US")
Wall Mural Abstract polygon background. Brazil flag colors. Vector. - PIXERS.US
NASA ECCO - Meeting Documents (Detail)
Ultrathin Hafnium Disulfide Atomic Crystals with ROS-Scavenging and Colon-Targeting Capabilities for Inflammatory Bowel Disease Treatment | ACS Nano
Vikte Lionikaite1, Alistair S Curry1, Audrey E Brown1
European Crohn´s and Colitis Organisation - ECCO - The 13th Congress of ECCO in numbers
/wall-murals-polygon-abstract-background-vector.jpg.jpg "Wall Mural Polygon abstract background. Vector. - PIXERS.US")
Wall Mural Polygon abstract background. Vector. - PIXERS.US
Infusion : Nov/Dec 2018
Kurzmeldungen und Impressionen vom ECCO-Kongress 2018 – Rosenfluh.ch
Accepted Manuscript
Table of Contents page: European Journal of Cancer
PDF) DOP037 A model for prediction of early surgery and complications in paediatric Crohn's disease: results of the prospective GROWTH CD study
ScholarWorks@BGSU - Educators in Context & Community Conference: 2014 Educators in Context and Community Conference Program
Bertrand Delsuc on Twitter: "AbbVie $ABBV upadacitinib (oral JAK1i) in CD - CELEST study #ECCO18 https://t.co/QkWKXzzbKb https://t.co/uDuNljBrSN" / Twitter
European Crohn´s and Colitis Organisation - ECCO - ECCO News
Bertrand Delsuc on Twitter: "AbbVie $ABBV upadacitinib (oral JAK1i) in CD - CELEST study #ECCO18 https://t.co/QkWKXzzbKb https://t.co/uDuNljBrSN" / Twitter
PDF) 4th Congress of ECCO Inflammatory Bowel Diseases Impact of antiTNF treatment on Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: real world data in Germany
ESR News May 2018
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis - Digestive and Liver Disease
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. - Document - Gale Academic OneFile
Discussion Late Breaking Abstracts (52298) | CRs | ena30 | ecco | meta-dcr
Bertrand Delsuc on Twitter: "AbbVie $ABBV upadacitinib (oral JAK1i) in CD - CELEST study #ECCO18 https://t.co/QkWKXzzbKb https://t.co/uDuNljBrSN" / Twitter
PDF) OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM
Bertrand Delsuc on Twitter: "AbbVie $ABBV upadacitinib (oral JAK1i) in CD - CELEST study #ECCO18 https://t.co/QkWKXzzbKb https://t.co/uDuNljBrSN" / Twitter
PDF) A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn's disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
European Crohn´s and Colitis Organisation - ECCO - Published ECCO Topical Reviews
